HZNP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HZNP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-06-08), Horizon Therapeutics's current share price is $116.30. Horizon Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2023 was $2.12. Horizon Therapeutics's Cyclically Adjusted Price-to-FCF for today is 54.86.
The historical rank and industry rank for Horizon Therapeutics's Cyclically Adjusted Price-to-FCF or its related term are showing as below:
During the past years, Horizon Therapeutics's highest Cyclically Adjusted Price-to-FCF was 685.14. The lowest was 36.84. And the median was 67.19.
HZNP's Cyclically Adjusted Price-to-FCF is not rankedThe Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.
Horizon Therapeutics's adjusted free cash flow per share data for the three months ended in Jun. 2023 was $0.611. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $2.12 for the trailing ten years ended in Jun. 2023.
The historical data trend for Horizon Therapeutics's Cyclically Adjusted Price-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Horizon Therapeutics Quarterly Data | ||||||||||||||||||||
Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
Cyclically Adjusted Price-to-FCF | Get a 7-Day Free Trial | 54.79 | 36.85 | 59.75 | 54.45 | 48.50 |
For the Drug Manufacturers - General subindustry, Horizon Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Horizon Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:
* The bar in red indicates where Horizon Therapeutics's Cyclically Adjusted Price-to-FCF falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.
Horizon Therapeutics's Cyclically Adjusted Price-to-FCF for today is calculated as
Cyclically Adjusted Price-to-FCF | = | Share Price | / | Cyclically Adjusted FCF per Share |
= | 116.30 | / | 2.12 | |
= | 54.86 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Horizon Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2023 is calculated as:
For example, Horizon Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2023 was:
Adj_FreeCashFlowPerShare | = | Free Cash Flow per Share | / | CPI of Jun. 2023 (Change) | * | Current CPI (Jun. 2023) |
= | 0.611 | / | 119.6619 | * | 119.6619 | |
= | 0.611 |
Current CPI (Jun. 2023) = 119.6619.
Horizon Therapeutics Quarterly Data
Free Cash Flow per Share | CPI | Adj_FreeCashFlowPerShare | |
201309 | -0.151 | 100.274 | -0.180 |
201312 | -0.180 | 99.875 | -0.216 |
201403 | -0.019 | 100.573 | -0.023 |
201406 | 0.221 | 100.773 | 0.262 |
201409 | 0.008 | 100.474 | 0.010 |
201412 | 0.073 | 99.576 | 0.088 |
201503 | -0.576 | 99.975 | -0.689 |
201506 | 0.256 | 100.573 | 0.305 |
201509 | 0.516 | 100.274 | 0.616 |
201512 | 0.818 | 99.676 | 0.982 |
201603 | 0.292 | 99.676 | 0.351 |
201606 | 0.257 | 101.072 | 0.304 |
201609 | 0.788 | 100.274 | 0.940 |
201612 | 0.856 | 99.676 | 1.028 |
201703 | 0.144 | 100.374 | 0.172 |
201706 | 0.287 | 100.673 | 0.341 |
201709 | 0.410 | 100.474 | 0.488 |
201712 | 0.871 | 100.075 | 1.041 |
201803 | -0.447 | 100.573 | -0.532 |
201806 | 0.373 | 101.072 | 0.442 |
201809 | 0.491 | 101.371 | 0.580 |
201812 | 0.629 | 100.773 | 0.747 |
201903 | 0.314 | 101.670 | 0.370 |
201906 | 0.465 | 102.168 | 0.545 |
201909 | 0.428 | 102.268 | 0.501 |
201912 | 0.672 | 102.068 | 0.788 |
202003 | -0.955 | 102.367 | -1.116 |
202006 | 0.512 | 101.769 | 0.602 |
202009 | 0.427 | 101.072 | 0.506 |
202012 | 1.460 | 101.072 | 1.729 |
202103 | -0.099 | 102.367 | -0.116 |
202106 | 0.321 | 103.364 | 0.372 |
202109 | 1.427 | 104.859 | 1.628 |
202112 | 2.180 | 106.653 | 2.446 |
202203 | 0.748 | 109.245 | 0.819 |
202206 | 1.012 | 112.779 | 1.074 |
202209 | 1.430 | 113.504 | 1.508 |
202212 | 1.626 | 115.436 | 1.686 |
202303 | 0.202 | 117.609 | 0.206 |
202306 | 0.611 | 119.662 | 0.611 |
Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.
Thank you for viewing the detailed overview of Horizon Therapeutics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Andy Pasternak | officer: EVP and Chief Business Officer | C/O HORIZON THERAPEUTICS PLC, CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD, DUBLIN L2 D04 C5Y6 |
Aaron Cox | officer: EVP, Chief Financial Officer | C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4 |
Jeffrey W Sherman | officer: EVP & Chief Medical Officer | C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618 |
Patrick Mcilvenny | officer: Chief Accounting Officer | C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4 |
Sean M. Clayton | officer: EVP, General Counsel | C/O HORIZON THERAPEUTICS PLC, 70 SAINT STEPHENS GREEN, DUBLIN L2 D02 E2X4 |
Thompson Elizabeth H.z. | officer: EVP, Research & Development | C/O HORIZON THERAPEUTICS, INC., 2 TOWER PLACE, 12TH FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Timothy P Walbert | director, officer: President, Chairman and CEO | 1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062 |
Jacopo Leonardi | officer: Chief Commercial Officer | C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4 |
Paul W. Hoelscher | officer: EVP Finance | 1 HORIZON WAY, C/O HORIZON THERAPEUTICS, INC., DEERFIELD IL 60015 |
Michael A. Desjardin | officer: EVP, Technical Operations | C/O JAZZ PHARMACEUTICALS, INC., 3180 PORTER DRIVE, PALO ALTO CA 94304 |
Miles W Mchugh | officer: Principal Accounting Officer | C/O ACCRETIVE HEALTH, INC., 401 N. MICHIGAN AVE, SUITE 2700, CHICAGO IL 60611 |
Barry Moze | officer: EVP, Corporate Dev't. | C/O HORIZON PHARMA, INC., 520 EAST COOK ROAD, SUITE 520, DEERFIELD IL 60015 |
Brian K Beeler | officer: EVP, General Counsel | C/O HORIZON PHARMA PLC, 520 LAKE COOK ROAD, SUITE 520, DEERFIELD IL 60015 |
Michael G Grey | director | C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121 |
William F Daniel | director | TREASURY BUILDING, LOWER GRAND CANAL STREET, DUBLIN 2 L2 00000 |
From GuruFocus
By Business Wire • 10-02-2023
By Business Wire • 08-09-2023
By Business Wire • 07-28-2023
By Business Wire • 10-02-2023
By Business Wire • 10-03-2023
By Business Wire • 07-28-2023
By Business Wire • 09-27-2023
By Business Wire • 10-06-2023
By Business Wire • 07-28-2023
By Business Wire • 09-19-2023